QLUPOD AG: Enquiries for QluPod from India!

Qlupod AG expands international reach: cooperation enquiries and LOI from India

Herisau (pta028/15.07.2024/18:00 UTC+2)

Published on 15. July 2024 by Qlupod AG

Herisau, Switzerland Qlupod AG (www.qlupod.com)

Qlupod AG, a start-up company in the field of telemedicine, is pleased to announce that it has received the first significant cooperation enquiries from India. After signing the corresponding non-disclosure agreements (NDA), the company has already received a letter of intent (LOI). The LOI covers the delivery of 35,000 to 40,000 QluPod health monitors in the first year. This is to be followed by a continuous increase to between 80,000 and 120,000 devices delivered from the third year of the collaboration.

Expansion strategy in less developed countries shows positive results

"We are very pleased with the positive feedback we have received from a country whose healthcare does not meet European standards. This confirms the strategic orientation of Qlupod AG to expand into less developed countries in order to significantly improve and permanently guarantee medical care for a large population," explains Sales Director Aidan Burley.

"The management is aware that the margins in these countries are lower than in more developed countries on the European market," adds Nikola Trajanov, Interim CEO and Partner of Qlupod AG. "However, the high number of sales will far outweigh the disadvantage of lower margins. In addition, our main future revenue will not only come from the sale of the hardware, but also from the proprietary QluPod app, the associated software and other sources of income," adds Nikola Trajanov.

Four sources of income ensure the independence and success of Qlupod AG

The sale of the QluPod health monitor for measuring six vital signs is not the only source of income for the company. As a start-up in the field of telemedicine, QluPod AG relies on these four sources of income:

1. Sale of devices: In addition to the QluPod health monitor, which has already successfully established itself on the market, further innovative products are currently being planned. These include a measuring device for continuous glucose monitoring (Continuous Glucose Monitoring CGN), the Qlu-Ring and other devices that are also in the planning phase.
2. Revenue from the proprietary QluPod app and software solutions: QluPod offers various apps tailored to users, such as QluPro for device users, QluDoc for doctors providing treatment and QluCare for retirement homes, assisted living or outpatient care services or, in Switzerland, for outpatient assistance and care (Spitex), for which users pay a fee.
3. Income from doctors' consultations via QluDoc: Using the QluDoc app enables doctors to advise their patients efficiently and safely without a personal consultation. This saves users travelling to the doctor's surgery and ensures reliable scheduling for the doctors treating them. In addition, regular contact strengthens the bond between doctor and patient, while the success of a therapeutic measure or medication can be checked in real time.
4. Shop for medicines and dietary supplements: In co-operation with partners such as online pharmacies, QluPod offers a comprehensive shop for medicines and dietary supplements, which represents a further source of income.

Potential of the telemedicine market until 2032

The forecasts for the telemedicine market are extremely promising. The American management consultancy Global Markets Insights Inc. expects the telemedicine sector in Europe to exceed USD 66 billion by 2032. For the global telemedicine market, the German online platform Statista expects a sales volume of around USD 244 billion for the same period. QluPod AG believes it is in an excellent position to gain significant market share and achieve long-term success. Its success is guaranteed by its innovative products, applications and services as well as its strategy of expanding into less developed countries.

A look into the future

The new partnerships and cooperation enquiries from India show that QluPod AG's innovative technology and strategic focus on global markets are being well received by healthcare providers and care service providers worldwide. This opens up numerous sales opportunities from which the company's other products and services also benefit. With its existing offerings and promising new developments such as the Qlu-Ring and the CGN measuring device, the company is well positioned to continue to grow and expand in the coming years. This brings QluPod AG ever closer to its goal of improving global healthcare alongside growth and financial success.

About Qlupod:

Qlupod AG is a start-up company in the field of telemedicine and develops innovative solutions to make patient care efficient and cost-effective. With the QluPod device and the associated software, the company is endeavouring to shape the future of healthcare. The offering is aimed at hospitals, care facilities, medical professionals and private individuals who want to monitor their health independently.

For more information about Qlupod AG and our products, please visit our website at www.qlupod.com.

Disclaimer:

This publication constitutes neither an offer to sell nor a solicitation to buy securities. Insofar as this document contains forward-looking statements, these do not represent facts and are characterised by the words "expect", "believe", "estimate", "intend", "aim", "assume" and similar expressions. These statements express the intentions, opinions or current expectations and assumptions of Qlupod AG and are based on current plans, estimates and forecasts which Qlupod AG has made to the best of its knowledge, but do not claim to be correct in the future. Forward-looking statements are subject to risks and uncertainties that are difficult to predict and are usually beyond the control of Qlupod AG. It should be noted that actual events or developments may differ materially from the events and developments expresse

(end)

Emitter:	QLUPOD AG Bahnhofstrasse 23 9100 Herisau Switzerland
Contact Person:	QluPod AG
Phone:	+41 71 510 05 45
E-Mail:	ir@qlupod.com
Website:	qlupod.com
ISIN(s):	CH1222316429 (Share)
Stock Exchange(s):	-
Other Stock Exchanges:	Regelmaessige Kursfeststellung Schweiz